Other genetic polymorphisms in other genes have been associated with the effectiveness of teriflunomide (DHODH (rs3213422)), alemtuzumab (CD52 (rs107184 and rs17645)), and cladribine (RRM1 (rs11030918 and rs12806698), and RRM2 (rs1042927 and rs1138729)) in pathologies with features in common in MS. This evidence concerns the gene CD52 and myeloid sarcoma.